Abstract 1742
Background
In Japan, gemcitabine based chemotherapy has been a standard regimen as one of the first-line treatment for unresectable pancreatic cancer. FOLFIRINOX was introduced in the second-line treatment for the gemcitabine-refractory pancreatic cancer of patients with an ECOG performance status score of 0 or 1. However, FOLFIRINOX requires close monitoring and must be limited to patients with good performance status because of significant toxicity. Further FOLFIRINOX requires a central veins port, and a trouble such as the port infection may occur. Therefore, it is difficult to administer FOLFIRINOX as second-line treatment. The first time in the world, we introduced IRISOX which substituted S-1 for fluorouracil and leucovorin in the second-line treatment. We aimed to evaluate the tolerance, safety, and clinical efficacy of IRISOX in the second-line treatment for the gemcitabine-refractory pancreatic cancer in a phase 1 study.
Methods
The primary objective was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of IRISOX. The study was designed in accordance with a standard 3 + 3 method. Patients received 2-week cycles of treatment. Irinotecan was administered as an intravenous infusion at 100, 120, or 150 mg/m2 on day 1, S-1 was administered orally at 80 mg/m2 twice daily for 7 days, and oxaliplatin was administered as an intravenous infusion at 85 mg/m2 on day 1.
Results
Among the 12 patients enrolled, dose-limiting toxicity was observed in a patient at level 1 (irinotecan 100 mg/ m2 on day 1, S-1 80 mg/m2 twice daily, and oxaliplatin 85 mg/m2 on day 1) , and in two patients at level 2 (irinotecan 120 mg/ m2 on day 1, S-1 80 mg/m2 twice daily, and oxaliplatin 85 mg/m2 on day 1). The MTD was established as level 2. The RD was established as level 1. The most common grade 3-4 toxicity was neutropenia (33.3 %). The overall response rate was 9.0 %. The overall disease control rate was 45.4 %.
Conclusions
Based on the present results, the RD was determined as level 1 (irinotecan 100 mg/ m2 on day 1, S-1 80 mg/m2 twice daily, and oxaliplatin 85 mg/m2 on day 1). IRISOX was well tolerated and showed antitumor efficacy in the second-line treatment for the gemcitabine-refractory pancreatic cancer in a phase 1 study.
Clinical trial identification
UMIN000022964.
Legal entity responsible for the study
Kitasato University School of Medicine, Japan.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract